Dashboard
1
Poor Management Efficiency with a low ROCE of 0.86%
- The company has been able to generate a Return on Capital Employed (avg) of 0.86% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 10.89% and Operating profit at -217.30% over the last 5 years
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,648 Million (Mid Cap)
NA (Loss Making)
NA
0.00%
3.92
-149.66%
81.24
Revenue and Profits:
Net Sales:
128 Million
(Quarterly Results - Mar 2026)
Net Profit:
6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.34%
0%
-16.34%
6 Months
-19.46%
0%
-19.46%
1 Year
40.56%
0%
40.56%
2 Years
101.38%
0%
101.38%
3 Years
-13.65%
0%
-13.65%
4 Years
168.98%
0%
168.98%
5 Years
207.03%
0%
207.03%
Lifecome Biochemistry Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.89%
EBIT Growth (5y)
-217.30%
EBIT to Interest (avg)
1.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-14.84
Sales to Capital Employed (avg)
0.68
Tax Ratio
5.88%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.86%
ROE (avg)
0.92%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
99.65
EV to EBIT
-77.72
EV to EBITDA
485.41
EV to Capital Employed
13.10
EV to Sales
13.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-16.86%
ROE (Latest)
-220.50%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
128.30
141.90
-9.58%
Operating Profit (PBDIT) excl Other Income
14.80
6.80
117.65%
Interest
5.40
12.50
-56.80%
Exceptional Items
0.00
0.00
Consolidate Net Profit
6.00
-29.30
120.48%
Operating Profit Margin (Excl OI)
115.10%
-140.70%
25.58%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -9.58% vs -11.53% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 120.48% vs 7.28% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
515.60
649.40
-20.60%
Operating Profit (PBDIT) excl Other Income
16.50
-112.50
114.67%
Interest
54.20
62.50
-13.28%
Exceptional Items
-2.60
-174.10
98.51%
Consolidate Net Profit
-139.30
-446.00
68.77%
Operating Profit Margin (Excl OI)
-163.40%
-330.10%
16.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -20.60% vs 28.09% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 68.77% vs -100.36% in Dec 2024
About Lifecome Biochemistry Co., Ltd. 
Lifecome Biochemistry Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






